Trovagene Expands NPM Patent Coverage

                    Trovagene Expands NPM Patent Coverage

PR Newswire

SAN DIEGO, Sept. 25, 2013

SAN DIEGO, Sept. 25, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ: TROV), a
developer of cell-free molecular diagnostics, announced the issuance of U.S.
Patent 8,501,924, "Nucleophosmin protein (NPM) mutants, corresponding gene
sequences and uses thereof." The patent pertains to nucleic acid sequences
encoding NPM mutants and methods of detecting them for diagnosing acute
myeloid leukemia (AML) and monitoring residual AML disease. This is the second
issued U.S. patent directed to NPM mutants, and is part of a NPM-associated
family of patents and applications for Trovagene. Previously, Trovagene
announced issuance of U.S. Patent 8,222,370, the first patent to issue in the
U.S. Additional claims directed to detecting NPM mutations are pending in the
U.S. and abroad.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"While the NPM patent family is an asset that has value as an incremental
revenue stream, Trovagene continues to develop its cell-free molecular
diagnostic tests for cancer monitoring," states Antonius Schuh, Ph.D., chief
executive officer of Trovagene. "Currently, Trovagene has licensing programs
with multiple organizations including Labcorp, Quest Labs, Genoptix, Duke
University and others. We intend to continue to develop additional licensing
relationships that can add supplemental value."

The National Comprehensive Cancer Network (www.nccn.org), which sets clinical
standards for cancer treatment, has included testing for NPM mutations in
their clinical practice guidelines. Mutation analysis of nucleophosmin-1
(NPM1) helps physicians to select more appropriate treatment strategies for
AML patients. NPM1 testing may also be useful for monitoring the effectiveness
of treatment, minimal residual disease monitoring and detecting relapse, and
stratifying AML patients when enrolling in clinical trials.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented
technology for the detection of cell-free DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that can be
isolated and detected from urine. Trovagene has a strong intellectual property
asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and
European patent applications and issued patents that cover testing for HPV and
other infectious diseases, cancer, transplantation, prenatal and genetic
testing.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or fourth party payer reimbursement; limited sales
and marketing efforts and dependence upon fourth parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2012 and other periodic reports filed with the
Securities and Exchange Commission.

Contact:
Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
Trovagene, Inc.
858-952-7594
szaniboni@trovagene.com

SOURCE Trovagene, Inc.

Website: http://www.trovagene.com
Website: http://www.nccn.org